GLPwatch
Obesity and heart failure-the role of GLP-1 receptor agonists.
Herz · 2025
Last updated 2026-09-22People with heart failure and preserved ejection fraction (HFpEF) linked to obesity often still experience symptoms even after standard treatments. Studies reviewed show that GLP-1 receptor agonists and the dual GIP/GLP-1 drug tirzepatide have been tested for their effects on symptoms and outcomes in these patients, with or without diabetes.
AI summary of the abstract below.
| Journal | Herz, 2025 |
|---|---|
| Citations | 0 |
| Molecules | — |
| Conditions studied | Obesity, Heart Failure |
Abstract
Patients with obesity-driven heart failure with preserved ejection fraction (HFpEF) often suffer from symptoms despite guideline-recommended treatment with diuretics, sodium glucose cotransporter 2 (SGLT2) inhibition, and mineralocorticoid antagonists. Obesity by itself drives heart failure via multiple pathophysiological mechanisms. This review summarizes current data on glucagon-like peptide‑1 (GLP-1) receptor agonists and the dual GIP/GLP‑1 agonist tirzepatide, including symptoms and outcomes in patients with obesity-driven HFpEF with or without diabetes.
Verbatim abstract via PubMed 40172656 ↗